Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The DRAFFT-2 trial has completed recruitment and will now begin its follow up phase.


When patients are treated in the operating theatre for a broken wrist, the surgeon will regularly use either a cast or wires to hold the wrist in place. At the moment we don't know whether the cast or wire is better, and whether one is more expensive than the other. DRAFFT-2 is comparing cast and wires to see which treatment is better, by asking patients about their wrist for a year after their injury.

Since early 2017, patients with broken wrists who were admitted to one of 36 participating hospitals in England and Wales have been enrolling in DRAFFT-2, and we have now finished the recruitment part of the study. Thank you to all the patients who are taking part, and well done to clinical and research staff at all the hospitals who have helped with the study!

For the next year we will be asking participants to complete questionnaires to tell us how their wrist is recovering and about any issues they have had along the way. In Summer/Autumn 2020 we will be able to calculate which treatment is better, publish the results in medical journals, and put a summary of the results on our website and in leaflets at participating hospitals.

DRAFFT-2 is funded by the National Institute for Health Research Health Technology Assessment programme (ID: 15/27/01).

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.